Rubicon Research Limited (NSE:RUBICON)

India · Delayed Price · Currency is INR

1,491.00

-9.20 (-0.61%)

At close: Jul 31, 2026

140.48% (1Y)

Market Cap	245.64B
Revenue (ttm)	17.54B +105.4%
Net Income	2.47B +171.1%
EPS	15.31 +159.1%
Shares Out	164.75M
PE Ratio	97.39
Forward PE	72.20
Dividend	1.50 (0.10%)
Ex-Dividend Date	n/a

Volume	145,535
Open	1,502.50
Previous Close	1,500.20
Day's Range	1,476.10 - 1,529.00
52-Week Range	570.75 - 1,589.70
Beta	n/a
Analysts	Strong Buy
Price Target	1,395.00 (-6.44%)
Earnings Date	Aug 3, 2026

About Rubicon Research

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, ... [Read more]

Industry Pharmaceutical Preparations

Founded 1999

Employees 903

Stock Exchange National Stock Exchange of India

Ticker Symbol RUBICON

Full Company Profile

Financial Performance

In fiscal year 2026, Rubicon Research's revenue was 17.54 billion, an increase of 36.57% compared to the previous year's 12.84 billion. Earnings were 2.47 billion, an increase of 83.63%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for RUBICON stock is "Strong Buy." The 12-month stock price target is ₹1,395, which is a decrease of -6.44% from the latest price.

Price Target

₹1,395

(-6.44% downside)

Analyst Consensus: Strong Buy

Stock Forecasts